Lupin launches authorized Generic Version of Duexis® in the United States

Global pharma major Lupin Limited (Lupin) today announced the launch of the authorized generic version of Duexise (ibuprofen and famotidine) Tablets, 800 mg/26.6 mg, of Horizon Medicines LLC.

Ibuprofen and Famotidine Tablets, 800 mg/26.6 mg, are indicated for the relief of signs and symptoms of rheumatoid arthritis, osteoarthritis and to decrease the risk of developing upper gastrointestinal ulcers, which in the clinical trials was defined as a gastric and/or duodenal ulcer in patients who are taking ibuprofen for those indications.

Ibuprofen and Famotidine Tablets (RLD: Duexis*) had estimated annual sales of USD 765 million in the U.S. (IQVIA MAT July 2021).

Shares of Lupin Ltd was last trading in BSE at Rs. 981 as compared to the previous close of Rs. 983.9. The total number of shares traded during the day was 27641 in over 1033 trades.

The stock hit an intraday high of Rs. 990.05 and intraday low of 979.5. The net turnover during the day was Rs. 27176508.

Source : Equity Bulls

Keywords